This is the authors' abstract. We don't add key points for this paper.
Bezinover et al1 should be congratulated on their recent article, Perioperative Coagulation Management in Liver Transplant Recipients. This article summarizes contemporary strategies from leaders in transplant in regard to coagulation in liver transplantation, which remains a challenging and controversial topic. As the recommendations focus on treating bleeding during the perioperative period, we would like to provide a data-driven perspective from the frontlines regarding coagulation monitoring during liver transplantation. This is essential, because the treatment of bleeding differs during the operative and postoperative course for each patient. Changes in coagulation during liver transplant surgery have been described by Dr. Starzl and colleagues since the 1960s.2 Predictable patterns of hypocoagulation occur during the anhepatic phase of surgery and during the early post graft reperfusion period. This is particularly true in regard to the fibrinolytic system in which patients are almost universally hyperfibrinolytic without a functioning liver, which is the primary clearance source of systemic tissue plasminogen activator. However, empiric inhibition of fibrinolysis has not been advocated in liver transplantation because the freshly transplanted liver can effectively correct hyperfibrinolysis, and historic data have demonstrated pulmonary embolism and even deaths with preemptive antifibrinolytics.3 It has been shown that by 2 hours of graft reperfusion, fibrinolysis resistance occurs without antifibrinolytics4 (Figure 1). Although patients may continue to bleed during this time frame from other hemostatic disorders, such as platelet dysfunction and fibrinogen deficiency, the risk of overcorrecting coagulopathy becomes a higher threat of thrombotic complications, as the endogenous machinery used to clear intravascular clot is impaired. This early transition to fibrinolysis resistance has been reported as far back in 1989.5 More recently, others have expressed concerns that bleeding is a less frequent complication during liver transplantation and that hypercoagulability is becoming a major problem.6FIGURE 1: Y axis represents the percent fibrinolysis (LY30) in blood samples obtained in liver transplant patients over the first 24 hours from surgery using the tissue plasminogen activator challenge thromboelastography. Dashed lines represent the interquartile range of 160 healthy volunteers using the same assay. At 120 minutes after graft reperfusion, almost all patients became resistant to tissue plasminogen activator. By postoperative day 1, less than half of patient has regained an LY30 within the interquartile range of healthy volunteers.At the surgeon level, we would advocate that early aggressive hemostatic resuscitation is indicated with even empiric blood products before graft reperfusion and resuscitation. However, in the immediate perioperative period, the data suggest that a more goal-directed approach should be used, particularly 2 hours after graft reperfusion to avoid excessive blood products and resultant pathologic hypercoagulability. At the system level, we agree that the transplant community should appreciate that the management of coagulation during liver transplantation is multifactorial and should not be isolated to treatment of bleeding. The recommendations presented by Bezinover et al provide a much needed guidance for future innovative research in coagulation. As the community continues to move forward in translating research from the bench to the bedside, we anticipate that the most effective treatment strategies will be applied to the right patient at the right time.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bababekov et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: